Two decades of randomized trials and registry data back EECP as a safe, effective treatment for angina, heart failure, and coronary artery disease. Below, the studies that shaped its FDA clearance and Medicare coverage.
Journal of the American College of Cardiology · Arora et al.
The first major randomized, sham-controlled trial. 139 patients with stable angina across 7 centers. Demonstrated significant reduction in angina episodes and nitroglycerin use, plus improved exercise duration vs. sham treatment.
University of Pittsburgh · ~8,000 patients across 200+ sites
The largest real-world EECP dataset. Tracked outcomes across multiple cohorts, confirming durable angina relief, improved quality of life, and reduced hospitalizations at 1, 2, and 3-year follow-ups.
Journal of the American College of Cardiology · Feldman et al.
187 patients with NYHA Class II–III heart failure. Compared EECP plus optimal medical therapy vs. optimal medical therapy alone. Demonstrated improved exercise capacity and quality of life.
Lawson et al.
Compared healthcare utilization before and after EECP in patients with refractory angina. Found a significant reduction in hospitalizations over the course of 1 year following therapy.
Guideline recommendation for refractory angina in the American College of Cardiology / American Heart Association guidelines.
Cleared for angina, heart failure, cardiogenic shock, and acute MI since 2002.
National Coverage Determination for chronic stable angina unresponsive to medical therapy.
of patients experience meaningful angina relief after 35 sessions.
typical duration of symptom improvement post-treatment (IEPR registry).
average improvement in Canadian Cardiovascular Society angina class.
serious adverse event rate across registry data.
We’ll walk you through the evidence and whether EECP fits your case.
